Dr. Reddy's Laboratories Ltd (RDY) News
Filter RDY News Items
RDY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RDY News Highlights
- RDY's 30 day story count now stands at 2.
- Over the past 8 days, the trend for RDY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- COYA and SA are the most mentioned tickers in articles about RDY.
Latest RDY News From Around the Web
Below are the latest news stories about DR REDDYS LABORATORIES LTD that investors may wish to consider to help them evaluate RDY as an investment opportunity.
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World IndexHYDERABAD, India, December 14, 2023--Dr. Reddy’s has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agenda. |
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)HOUSTON & HYDERABAD, India & BASEL, Switzerland, December 06, 2023--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), and Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya"), today announced that they have entered into a development and license agreement (the "Agreement") for the development and commercialization of COYA 302, an investigatio |
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat EstimatesDr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe. |
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call TranscriptDr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript October 27, 2023 Dr. Reddy’s Laboratories Limited beats earnings expectations. Reported EPS is $1.07, expectations were $0.88. Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy’s Q2 FY ’24 Earnings Conference Call. [Operator Instructions]. Please note that this conference is being recorded. […] |
Dr. Reddy’s Q2 FY24 Financial ResultsHYDERABAD, India, October 27, 2023--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023. |
All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong BuyDoctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. |
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerDoctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) NowDoctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. |